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Background: Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older
patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mortality
and morbidity. Stroke prevention is therefore a key management strategy for AF patients, in addition to rate and
rhythm control. Anticoagulation with warfarin has been an enduring gold standard for stroke prevention in NVAF
patients. In Australia, three novel oral anticoagulants (NOACs), apixaban, dabigatran and rivaroxaban are now
approved and reimbursed for stroke prevention in patients with non-valvular AF (NVAF). International European
Cardiology guidelines now recommend either a NOAC or warfarin for NVAF patients with a CHA2DS2-VASc
score ≥2, unless contraindicated. Apixaban is a direct factor Xa inhibitor with a 12-hour half-life and 25%
renal excretion that was found in a large trial of NVAF patients to be superior to warfarin in preventing stroke
or systemic embolism. In this trial population, apixaban also resulted in less bleeding and a lower mortality
rate than warfarin.
Methods: Clinical experience with apixaban outside of clinical trials has been limited, and there is currently
little evidence to guide the management of bleeding or invasive procedures in patients taking apixaban.
The relevant currently available animal and ex vivo human data were collected, analyzed and summarized.
Results: This multi-disciplinary consensus statement has been written to serve as a guide for healthcare practitioners
prescribing apixaban in Australia, with a focus on acute and emergency management.
Conclusions: The predictable pharmacokinetics and minimal drug interactions of apixaban should allow for safe
anticoagulation in the majority of patients, including temporary interruption for elective procedures. In the absence of
published data, patients actively bleeding on apixaban should receive standard supportive treatment. Quantitative
assays of apixaban level such as chromogenic anti-Xa assays are becoming available but their utility is unproven in this
setting. Specific antidotes for novel anticoagulants, including apixaban, are in clinical development.
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In Australia, three novel oral anticoagulants (NOACs)
have been approved for the prevention of stroke in pa-
tients with non-valvular atrial fibrillation (NVAF) and
one or more additional risk factors for stroke (prior
stroke, prior transient ischaemic attack, prior systemic
embolism, age ≥75 [or age ≥65 years associated with one
of the following: diabetes mellitus, coronary artery dis-
ease, or hypertension], arterial hypertension requiring
treatment, diabetes mellitus, heart failure ≥New York* Correspondence: cward@med.usyd.edu.au
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stated.Heart Association Class 2, decreased left ventricular
ejection fraction or documented peripheral arterial dis-
ease). These are dabigatran, a direct thrombin inhibitor,
and two direct factor Xa inhibitors, apixaban and rivar-
oxaban. All three are also approved in Australia for the
prevention of venous thromboembolic events (VTE) in
adult patients who have undergone major orthopaedic
surgery of the lower limb. Rivaroxaban is approved for
the treatment of deep vein thrombosis (DVT) and
pulmonary embolism (PE) and the prevention of re-
current venous thromboembolism. These novel oral anti-
coagulants have short half-lives (dabigatran 12-17 hrs,
apixaban ~12 hrs, rivaroxaban 5-13 hrs), predictabletd. This is an Open Access article distributed under the terms of the Creative
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actions, compared to warfarin. In addition to their
favourable pharmacokinetic profiles, dabigatran 110 mg
and rivaroxaban have demonstrated similar rates of stroke
and systemic embolism reduction to warfarin in NVAF
patients, with dabigatran 150 mg and apixaban dem-
onstrating a superior reduction in stroke and systemic
embolism, compared to warfarin [1-3]. Additionally,
dabigatran 110 mg and apixaban resulted in significantly
less major bleeding, compared to warfarin [1,3]. Although
specific antidotes for these agents are currently in devel-
opment, the lack of a reversal strategy has raised concern
among healthcare providers.
Methods
In the absence of robust clinical data for emergency and
peri-operative management of patients receiving apixa-
ban, an expert panel of Australian clinicians from the
fields of cardiology, neurology and haematology con-
vened to develop this practical consensus guide for apix-
aban management in Australia, utilising the currently
available animal and ex vivo human data.
Results and discussion
About apixaban
Apixaban is a direct FXa inhibitor with rapid onset of
action, a 12-hour half-life and only ~25% renal excretion
[4,5]. Apixaban is indicated in Australia for the preven-
tion of venous thromboembolic events (VTE) in adult
patients who have undergone elective total hip or total
knee replacement surgery and for the prevention of
stroke and systemic embolism in patients with non-
valvular atrial fibrillation and at least one additional risk
factor for stroke. The recommended dose of apixaban
for VTE prophylaxis is 2.5 mg BID. The recommended
dose of apixaban for stroke prevention in non-valvular
atrial fibrillation (NVAF) is 5 mg BID (2.5 mg BID if ≥2
of the following; ≤60 kg, ≥80 years, serum creatinine
level ≥133 μm/L) [5].
The risk of stroke and bleeding must be assessed for
each patient before commencing any anticoagulation ther-
apy, including apixaban. Some of the patients excluded
from the trials [3,6] had baseline characteristics that were
associated with increased risk of bleeding (e.g. recent
major bleeding, renal insufficiency [CrCl <25 ml/min],
severe hepatic impairment, platelet count <100), and
there are no or insufficient data on the use of apixa-
ban in such patients. The clinical trials excluded aspirin
doses >165 mg/day or dual anti-platelet therapy [3,6]. The
concomitant use of apixaban with anti-platelet agents in-
creases the risk of bleeding [7]. Apixaban should be used
with caution when co-administered with NSAIDs (inclu-
ding acetylsalicylic acid) because these medicinal products
typically increase the bleeding risk. A significant increasein bleeding risk was reported with the triple combination
of apixaban, acetylsalicylic acid and clopidogrel in a clin-
ical study in patients with acute coronary syndrome [8].
Laboratory measurement of apixaban
At present, there is no validated coagulation assay to
measure apixaban effect. As a result of FXa inhibition,
apixaban prolongs standard clotting tests such as pro-
thrombin time (PT), activated partial thromboplastin
time (aPTT) but with variability between reagents [9].
Increases in clotting times are small at best, and the PT
may remain normal (ratio <1.2) at a therapeutic concen-
tration of apixaban [9]. Therefore the PT and APTT are
not recommended to assess the pharmacodynamic ef-
fects of apixaban [5].
Specialised clotting assays can be used to measure
apixaban effects. Anti-FXa activity exhibits a close direct
linear relationship with apixaban plasma concentration,
reaching maximum values at the time of apixaban peak
plasma concentrations. The relationship between apixa-
ban plasma concentration and anti-FXa activity is linear
over a wide dose range of apixaban [10]. Although treat-
ment with apixaban at the recommended dose does not
require routine laboratory monitoring, measurement of
drug level by a chromogenic anti-FXa assay may be use-
ful in exceptional situations where knowledge of the
apixaban level may help to inform clinical decisions,
e.g. overdose or emergency surgery [5]. Anti-Xa assays
are generally available in large Australian teaching hospi-
tals, but may not be routinely performed in smaller insti-
tutions or after hours. These assays may also be difficult
to access in other countries, with significant delays in
reporting. Diagnostic laboratories will need validated,
commercial apixaban controls and calibrators to adapt
their anti-Xa assays for apixaban. Although commercial
research-use only apixaban-specific calibrators are cur-
rently available in Australia, a standard curve constructed
with commercial LMWH standards was reported to show
an equally strong correlation with apixaban plasma
concentration (r2 = 0.89) as one constructed with apix-
aban (r2 = 0.88) [11]. A dilute prothrombin time (dPT),
achieved by diluting the thromboplastin reagent in
100 mmol/L CaCl2, has been proposed as an improved
assay for factor Xa inhibitors [12]. This modification
prolonged the PT measurements at therapeutic con-
centrations of apixaban and showed greater sensitivity
than a standard PT [12]. However, others have found
that dPT was no better than PT in terms of sensiti-
vity [9], suggesting that further development of these
assays is needed.
The delay between the last intake of the drug and the
blood sampling should be considered when assessing
apixaban levels, since assays are influenced proportion-
ally to apixaban concentration [9].
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Apixaban is metabolized mainly by CYP3A4/5 and is a
substrate of efflux transport proteins P-glycoprotein (P-gp)
and Breast Cancer Resistance Protein [5]. Therefore, apixa-
ban is contraindicated in patients who are receiving con-
comitant treatment with strong inhibitors of both CYP3A4
and P-gp, such as azole-antimycotics or HIV protease in-
hibitors [5] e.g. ketoconazole, itraconazole, voriconazole,
posaconazole or ritonavir.
No dose adjustment for apixaban is required when this
is co-administered with less potent inhibitors of CYP3A4
and/or P-gp [5] such as diltiazem, naproxen, amioda-
rone, verapamil, clarithromycin or quinidine.
The concomitant use of apixaban with strong CYP3A4
and P-gp inducers may lead to reduced apixaban plasma
concentrations. No dose adjustment for apixaban is re-
quired during concomitant therapy with such agents, how-
ever strong inducers of both CYP3A4 and P-gp should be
co-administered with caution [5] e.g. rifampicin, phenytoin,
carbamazepine, phenobarbital and St John’s Wort.
Famotidine, a typical gastric acid suppressant, does not
affect the pharmacokinetics of apixaban [13]. As such,
increases in gastric pH due to other gastric acid modi-
fiers (such as other H2-receptor antagonists, proton
pump inhibitors, and antacids) or the presence of abnor-
mally elevated gastric pH (e.g. achlorhydria) are unlikely
to affect the pharmacokinetics of apixaban [13].
Starting apixaban
Prior to initiating apixaban, liver function and renal
function testing should be performed. The European
Society of Haematology 2012 guidelines recommend as-
sessment of renal function (by calculated CrCl) be
mandatory for all NOACs, with renal function being
assessed annually in patients with normal (CrCl ≥80 mL/
min) or mild (CrCl 50–79 mL/min) renal impairment,
and 2–3 times per year in patients with moderate (i.e. cre-
atinine clearance 30–49 mL/min) renal impairment [14].
Patients with impaired renal function (≤80 mL/min)
were at higher risk for all cardiovascular events during
the ARISTOTLE trial, and the incidence of major bleed-
ing increased significantly with increasing renal dysfunc-
tion [15]. Apixaban was associated with less major
bleeding compared with warfarin for three methods of
glomerular filtration rate estimation (Cockcroft–Gault,
Chronic Kidney Disease Epidemiology Collaboration and
cystatin C) and stroke or systemic embolism occurred
less frequently in patients assigned to apixaban than
warfarin, regardless of renal function [15].
Switching from warfarin to apixaban
When switching anticoagulation from warfarin to apixa-
ban, it is important to avoid using both drugs at thera-
peutic doses simultaneously; it is recommended that theINR is monitored daily after the cessation of warfarin,
and that apixaban is not started until the INR is <2.0,
typically approximately three days after cessation of
therapeutic warfarin [3].
Switching from low molecular weight heparin (LMWH) to
apixaban
As both agents have a similar rapid onset of FXa inhibition
and effective half-life, switching anticoagulation from
LMWH (e.g. enoxaparin) to apixaban, (and vice versa), can
simply be done at the time of the next scheduled dose [5].
Switching from apixaban
An increased risk of stroke was observed during the
transition from apixaban to warfarin in clinical trials
in patients with non-valvular atrial fibrillation [16].
Discontinuation of apixaban prior to the onset of an
effective antithrombotic effect of VKA could result in
an increased risk of thrombosis. If anticoagulation with
apixaban must be discontinued for any reason other than
pathological bleeding, consider coverage with another
anticoagulant.
Apixaban to warfarin
When converting from apixaban to warfarin, continue
apixaban for 48 hours after the first dose of warfarin.
After 2 days of co-administration of apixaban with war-
farin, obtain an INR prior to the next scheduled dose of
apixaban. Continue co-administration of apixaban and
warfarin until the INR is ≥ 2.0.
Apixaban to low molecular weight heparin (LMWH)
As both agents have a similar rapid onset of FXa inhib-
ition and effective half-life, switching anticoagulation from
apixaban to LMWH (e.g. enoxaparin) and vice versa, can
simply be done at the time of the next scheduled dose [5].
Bleeding management in patients receiving apixaban
In the ARISTOTLE study of apixaban in patients with
atrial fibrillation, annual major bleeding events for apixa-
ban compared to warfarin were 2.13% per year versus
3.09% per year (p < 0.001) [3]. Intracranial haemorrhage
events were 0.33% per year for apixaban, compared to
0.80% per year for warfarin (p < 0.001) [3].
Spontaneous bleeding may occur with any anticoagu-
lant. In the absence of published data regarding the
treatment of patients with active bleeding while recei-
ving apixaban, the following advice for general manage-
ment of bleeding events is based on expert consensus
(Figure 1).
 Establish the primary source of bleeding wherever
possible, and secure haemostasis with local
measures.
Figure 1 Considerations for the management of bleeding, based on expert consensus.
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cessation of drug, standard supportive treatment,
including transfusion, mechanical compression and
other local measures.
 If bleeding occurs within 6 hours of last apixaban
dose, activated charcoal may reduce apixaban
absorption, and hence anticoagulant effect [17].
This should also be considered soon after overdose
or accidental ingestion.
 A specific antidote for apixaban is not currently
available [5]. Two synthetic molecules are currently
in early clinical trials for apixaban reversal.
Andexanet alpha (PRT064445) is a truncated form
of enzymatically inactive factor Xa, which can dose-dependently reverse the inhibitory activity and
correct the prolongation of ex vivo clotting times by
apixaban and other factor Xa inhibitors [18]. Another
synthetic small molecule, aripazine (PER977), appears
to have broad activity against the NOACs, reversing
the anticoagulant activity of dabigatran, rivaroxaban,
apixaban and edoxaban in rat bleeding models [19].
 Apixaban is highly (~87%) protein bound, and hence
not expected to be dialyzable [5]. Based on studies
of other factor Xa inhibitors in healthy volunteers,
prothrombin complex concentrates (PCC) may
reverse the anticoagulant effect, however the effect
of PCC on clinical bleeding is not proven [20].
When apixaban (200 ng/ml) was added in vitro to
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were more effective at improving thrombin
generation than recombinant FVIIa (rFVIIa) [21].
 There is no clinical evidence examining the use of
rFVIIa or bypassing agents (FEIBA) in bleeding
patients receiving apixaban. In a rabbit model of
apixaban-induced bleeding, neither rFVIIa nor PCC
reduced blood loss from a standardised hepatosplenic
injury, although rFVIIa did reverse prolongation of
the prothrombin time and shortened skin bleeding
time [22]. When apixaban (200 ng/ml) was added
in vitro to blood from healthy donors, rFVIIa was
more effective than PCC in restoring clotting times
and thromboelastography parameters [21]. In animal,
in vitro and healthy volunteer studies, these agents
have partially reversed the anticoagulant effect of
apixaban and other factor Xa inhibitors [23-26]. These
agents can be considered for life-threatening bleeding,
but carry a proven risk of thrombosis.
 There is no evidence to support the use of FFP,
other than for volume replacement in case of major
bleeding.
Peri-operative management in patients receiving
apixaban
In stable patients, apixaban has a predictable half-life of
8-12 hours, which leaves residual activity of up to 50% at
12 hours and less than 25% at 24-hours after drug cessa-
tion [4]. This means that apixaban can be ceased for a
shorter period of time than warfarin before invasive pro-
cedures, without the routine need to bridge with alterna-
tive anticoagulants such as heparin.Figure 2 Perioperative dosing/elimination.Planning for elective surgery or invasive procedures
should involve balancing the intervention-associated
bleeding risk and thrombotic risk associated with anti-
coagulant interruption in each individual. A “safe” re-
sidual drug level of apixaban for surgery is presently
unknown, and no test has been correlated with bleeding
risk. As such, there is currently no known threshold at
which apixaban patients’ bleeding risk are able to be
comparable to non-apixaban treated patients [27].
In general, apixaban should be discontinued 2 to 3 days
prior to elective surgery or invasive procedures [5], as
outlined below and in Figure 2. There are small groups
of people at higher risk of thrombosis (e.g. CHADS2 > 5,
recent TIA or stroke) where an individualised approach is
needed to minimise the period of sub-therapeutic anticoa-
gulation. A recent review of periprocedural use of anti-
thrombotic therapy notes the importance of checking
creatinine clearance in patients on rivaroxaban and apixa-
ban, prior to cessation for high-risk procedures [28]. A
longer period of pre-operative discontinuation, up to
5 days, can be considered for patients with renal or hep-
atic impairment or other conditions associated with de-
creased drug elimination. In this setting, “bridging” with
LMWH has been proposed for patients with a high risk of
thrombosis [27]. Given the predictable pharmacokinetics
of apixaban, bridging with an alternative anticoagulant
should not be required in the majority of cases.
Advice for assessing peri-procedural dosing
High bleeding risk
Procedures with a high risk of bleeding (e.g. neurosurgical,
urological procedures, major abdominal or orthopaedic):
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of the procedure; last dose of drug should be 3 days
prior (5 missed doses including morning of surgery –
Figure 2) [29].
Low bleeding risk
Procedures with a low risk of bleeding (e.g. inguinal her-
nia repair, percutaneous biopsy, dental extractions): aim
to achieve minimal-mild residual apixaban effect at the
time of the procedure; last dose of drug should be 2 days
prior (3 missed doses including morning of surgery –
Figure 2) [29].
Minimal bleeding risk
For selected procedures with minimal risk of bleeding
(e.g. cataract surgery, skin cancer excision): therapeutic
anticoagulation may be continued.
Re-commencing apixaban after surgery
Re-commence apixaban dosing only once surgical
haemostasis has been secured (typically 24 hours after
surgery) [29]. In general, caution should be exercised
with re-instituting therapeutic anticoagulation within
the first 48 hours after surgery. Where there is a risk
of post-operative venous thrombosis and the bleeding
risk is high, consider a reduced dose of 2.5 mg BID
(recommended prophylactic dose) for the immediate
post-operative period.
In patients with poor oral absorption or nil by mouth
after surgery, parenteral anticoagulants may be needed
until reliable oral absorption is established.
Neuraxial anaesthesia
Indwelling epidural or intrathecal catheters must be re-
moved at least 5 hours prior to the first dose of apixa-
ban. Experience with neuraxial blockade is limited and
extreme caution is therefore recommended when using
apixaban in this setting (see P.I.) [5].
Conclusions
 Apixaban is a direct FXa inhibitor indicated in
Australia for the prevention of venous
thromboembolic events (VTE) in adult patients who
have undergone elective total hip or total knee
replacement surgery (2.5 mg BID) and for the
prevention of stroke and systemic embolism in
patients with non-valvular atrial fibrillation and at
least one additional risk factor for stroke (5 mg BID
or 2.5 mg BID if ≥2 of the following; ≤60 kg, ≥80 years,
serum creatinine level ≥133 um/L) [5].
 In the ARISTOTLE study of apixaban in patients
with atrial fibrillation, annual major bleeding events
for apixaban compared to warfarin were 2.13% peryear versus 3.09% per year (p < 0.001). Intracranial
haemorrhage events were 0.33% per year for
apixaban, compared to 0.80% per year for warfarin
(p < 0.001) [3].
 There is no standardised assay currently
commercially available in Australia to measure
apixaban effect. As apixaban minimally prolongs PT
or aPTT, these clotting tests are not recommended
to assess the pharmacodynamic effects of apixaban
[5]. A chromogenic anti Xa assay or dilute PT assay
may be useful, where knowledge of apixaban
exposure is required [10-12].
 Apixaban is contraindicated in patients who are
receiving concomitant treatment with strong
inhibitors of both CYP3A4 and P-gp, however no
dose adjustment for apixaban is required when
co-administered with less potent inhibitors. No dose
adjustment for apixaban is required during
concomitant therapy with strong CYP3A4 and P-gp
inducers, however they may lead to reduced apixaban
plasma concentrations [5].
 A specific antidote for apixaban is not currently
available, however specific anti-Xa inhibitor and
universal novel oral anticoagulant antidotes are in
clinical development [18,19].
 In the absence of published data regarding the
treatment of patients with active bleeding while
receiving apixaban, discontinue apixaban, apply
standard supportive treatment and other local
measures [5]. Activated charcoal may reduce
apixaban absorption within 6 h of last dose [17].
 Apixaban is not expected to be dialyzable, however
prothrombin complex concentrates (PCC) may
reverse the anticoagulant effect and recombinant
FVIIa or bypassing agents (FEIBA) can be
considered for life-threatening bleeding. FFP will not
reverse apixaban effect but can be used as volume
replacement in case of major bleeding.
 Planning for elective surgery or invasive
procedures should involve balancing the
intervention-associated bleeding risk and thrombotic
risk associated with anticoagulant interruption in
each individual.
Abbreviations
APTT: Activated partial thromboplastin time; ASA: Acetylsalicylic acid;
CrCl: Creatinine clearance; DVT: Deep vein thrombosis; FEIBA: Factor VIII
inhibitor bypassing agent; FX: Factor X; INR: International normalized ratio;
NOAC: Novel oral anticoagulants; NSAID: Non-steroidal antiflammatory drugs;
NVAF: Non-valvular atrial fibrillation; PCC: Prothrombin complex concentrates;
PE: Pulmonary embolus; PT: Prothrombin time; rFVIIa: Recombinant activated
Factor VII; VTE: Venous thromboembolism.
Competing interests
The authors received honoraria and travel support from Pfizer Australia to
review the literature and attend a working group meeting where this
consensus statement was generated.
Ward et al. Thrombosis Journal 2013, 11:27 Page 7 of 8
http://www.thrombosisjournal.com/content/11/1/27Authors’ contributions
CW contributed to consensus statement and wrote the manuscript;
GD contributed to consensus statement and reviewed the manuscript; ASG
contributed to consensus statement and reviewed the manuscript;
GC contributed to consensus statement and reviewed the manuscript;
SM contributed to consensus statement and reviewed the manuscript.
All authors read and approved the final manuscript.Acknowledgements
Dr Stephanie Lebret (Pfizer Australia) organized the working group meeting
and assisted the authors in the preparation of this manuscript.
Author details
1Kolling Institute, University of Sydney; Royal North Shore Hospital, Sydney,
NSW, Australia. 2Cardiovascular Diagnostic Services, Liverpool, NSW, Australia.
3Florey Institute of Neuroscience and Mental Health; The Austin Hospital,
Heidelberg, VIC, Australia. 4Flinders Medical Center, Bedford Park, SA,
Australia. 5Queen Elizabeth Hospital; Royal Adelaide Hospital, Woodville
South, SA, Australia.
Received: 18 September 2013 Accepted: 30 November 2013
Published: 31 December 2013References
1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D,
Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,
the RE-LY Steering Committee and Investigators: Dabigatran versus
warfarin in patients with atrial fibrillation. N Engl J Med 2009,
361:1139–5.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD,
Fox KA, Califf RM, and the ROCKET AF Steering Committee, for the ROCKET AF
Investigator: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med 2011, 365:883–891.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,
Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD,
Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S,
Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS,
Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al: ARISTOTLE
Committees and Investigators: apixaban versus warfarin in patients with
atrial fibrillation. New Engl J Med 2011, 365:981–992.
4. Frost C, Nepal S, Wang J, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves
RA, Lacreta F: Apixaban, an oral, direct factor Xa inhibitor: single-dose
safety, pharmacokinetics, pharmacodynamics and food effect in healthy
subjects. Br J Clin Pharmacol 2013, 75(2):476–487.
5. ELIQUIS® (Apixaban) Approved Product Information. Bristol-Myers Squibb
Australia Pty Ltd and Pfizer Pty Ltd; 2013. http://www.bmsa.com.au/products/
pages/Home.aspx.
6. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G,
Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A,
Jansky P, Commerford P, Tan RS, Sim K-H, Lewis BS, Van Mieghem W, Lip GYH,
Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M,
O’Donnell M, Lawrence J, Lewis G, et al: Apixaban in patients with
atrial fibrillation. N Engl J Med 2011, 364:806–817.
7. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL,
Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE,
Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D,
Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P,
Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, et al: Apixaban
with antiplatelet therapy after acute coronary syndrome. N Engl J
Med 2011, 365:699–708.
8. APPRAISE Steering Committee and Investigators, Alexander JH, Becker
RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG,
Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P,
Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L: Apixaban,
an oral, direct, selective Factor Xa inhibitor, in combination with
antiplatelet therapy after acute coronary syndrome. Circulation 2009,
119:2877–2885.9. Douxfils J, Chatelain C, Chatelain B, Dogné J-M, Mullier F: Impact of apixaban
on routine and specific coagulation assays: a practical laboratory guide.
Thromb Haemost 2013, 110(2):283–294.
10. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin LC, Alexander JH:
Chromogenic laboratory assays to measure the factor Xa-inhibiting
properties of apixaban—an oral, direct and selective factor Xa
inhibitor. J Thromb Thrombolysis 2011, 32:183–187.
11. Barrett YC, Wang Z, Frost C, Shenker A: Clinical laboratory measurement of
direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin
time assay. Thromb Haemost 2010, 104:1263–1271.
12. Barrett YC, Wang Z, Knabb RM: A novel prothrombin time assay for
assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl
Thromb Hemost 2012, 19(5):522–528.
13. Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, Lacreta F, Frost CE:
Effect of famotidine on the pharmacokinetics of apixaban, an oral
direct factor Xa inhibitor. Clin Pharmacol: Advances and Applications 2013,
5:59–66.
14. Camm AJ, Lip GY, Caterina R, Savelieva I, Atar D, Hohnloser SH, G H,
Kirchhof P, ESC Committee for Practice Guidelines (CPG): 2012 focused
update of the ESC Guidelines for the management of atrial fibrillation.
Eur Heart J 2012, 33:2719–2747.
15. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M,
Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L: Efficacy of
apixaban when compared with warfarin in relation to renal function
in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Eur Heart J 2012, 33:2821–2830.
16. Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J,
Hylek E, Ansell JE, Wallentin L, for the ARISTOTLE investigators: Events
after discontinuation of randomized treatment at the end of the
ARISTOTLE trial [abstract]. Eur Heart J 2012, 33(Abstract Supplement):
685–686.
17. Wang X, Tirucherai G, Pannacciulli, Wang J, Elsrougy A, Teslenko V, Chang M,
Zhang D, Frost C: Effect of activated charcoal on the pharmacokinetics of
apixaban in healthy subjects [abstract]. Clinical Pharmacol Ther 2012,
91(Suppl 1):s41.
18. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P,
Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Uma S: A specific
antidote for reversal of anticoagulation by direct and indirect inhibitors
of coagulation factor Xa. Nat Med 2013, 19(4):446–451.
19. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S:
Small molecule antidote for anticoagulants [abstract]. Circulation 2012,
126:A11395.
20. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M:
Reversal of rivaroxaban and dabigatran by prothrombin complex
concentrate: a randomized, placebo-controlled, crossover study in
healthy subjects. Circulation 2011, 124:1573–1579.
21. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P,
Diaz-Ricart M, Galan AM: Reversal of apixaban induced alterations of
hemostasis by different coagulation factor concentrates: studies
in vitro with circulating human blood [abstract]. Circulation 2012,
126:520–521.
22. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P,
Samama CM, Godier A: Evaluation of recombinant activated factor VII,
prothrombin complex concentrate, and fibrinogen concentrate to
reverse apixaban in a rabbit model of bleeding and thrombosis. Int J
Cardiol 2013, 168:4228–4233.
23. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD,
Chan AK, James A, Moll S, ORtel TL, Van Cott EM, Ansell J: Guidance on the
emergent reversal of oral thrombin and factor Xa inhibitors. Am J
Hematol 2012, 87(Suppl 1):S141–S145.
24. Bauer KA: Reversal of antithrombotic agents. Am J Hematol 2012,
87(Suppl 1):S119–S126.
25. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T: Reversal
of anticoagulant effects of edoxaban, an oral, direct factor Xa
inhibitor, with haemostatic agents. Thromb Haemost 2012,
107:253–259.
26. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G: Effect of
non-specific reversal agents on anticoagulant activity of dabigatran and
rivaroxaban. Thromb Haemost 2012, 108:217–224.
27. Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F,
Llau JV, Sierra P, Torres LM: The perioperative management of new direct
Ward et al. Thrombosis Journal 2013, 11:27 Page 8 of 8
http://www.thrombosisjournal.com/content/11/1/27oral anticoagulants: a question without answers. Thromb Haemost 2013,
110:515–522.
28. Baron TH, Kamath PS, McBane RD: Antithrombotic therapy and invasive
procedures. New Engl J Med 2013, 368:1079–1080.
29. Douketis JD: Pharmacologic properties of the new oral anticoagulants:
a clinician-oriented review with a focus on perioperative management.
Curr Pharm Des 2010, 16:3436–3441.
doi:10.1186/1477-9560-11-27
Cite this article as: Ward et al.: Practical management of patients on
apixaban: a consensus guide. Thrombosis Journal 2013 11:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
